Skip to main content
ACS AuthorChoice logoLink to ACS AuthorChoice
. 2024 Apr 4;23(5):1634–1648. doi: 10.1021/acs.jproteome.3c00752

Identification of the Most Immunoreactive Antigens of Candida auris to IgGs from Systemic Infections in Mice

Maialen Areitio , Aitziber Antoran †,*, Oier Rodriguez-Erenaga , Leire Aparicio-Fernandez , Leire Martin-Souto , Idoia Buldain , Beñat Zaldibar §, Alba Ruiz-Gaitan , Javier Pemán , Aitor Rementeria , Andoni Ramirez-Garcia
PMCID: PMC11077488  PMID: 38572994

Abstract

graphic file with name pr3c00752_0007.jpg

The delay in making a correct diagnosis of Candida auris causes concern in the healthcare system setting, and immunoproteomics studies are important to identify immunoreactive proteins for new diagnostic strategies. In this study, immunocompetent murine systemic infections caused by non-aggregative and aggregative phenotypes of C. auris and by Candida albicans and Candida haemulonii were carried out, and the obtained sera were used to study their immunoreactivity against C. auris proteins. The results showed higher virulence, in terms of infection signs, weight loss, and histopathological damage, of the non-aggregative isolate. Moreover, C. auris was less virulent than C. albicans but more than C. haemulonii. Regarding the immunoproteomics study, 13 spots recognized by sera from mice infected with both C. auris phenotypes and analyzed by mass spectrometry corresponded to enolase, phosphoglycerate kinase, glyceraldehyde-3-phosphate dehydrogenase, and phosphoglycerate mutase. These four proteins were also recognized by sera obtained from human patients with disseminated C. auris infection but not by sera obtained from mice infected with C. albicans or Aspergillus fumigatus. Spot identification data are available via ProteomeXchange with the identifier PXD049077. In conclusion, this study showed that the identified proteins could be potential candidates to be studied as new diagnostic or even therapeutic targets for C. auris.

Keywords: Candida auris, antigen, electrophoresis, proteomic, WB, mass spectrometry

Introduction

The species of the genus Candida are the main causative agents of invasive fungal infections,1 with species such as Candida albicans and Candida glabrata being mainly isolated from the majority of candidemia cases described.2 Nevertheless, in the last years, the incidence of candidemia cases caused by the new fungal species Candida auris has increased.3 In 2009, it was isolated for the first time from the outer ear canal of a 70-year-old woman in Japan.4 This emergent pathogen is multiresistant to antifungals,5,6 difficult to diagnose,7 and capable of producing nosocomial outbreaks that are difficult to eradicate.810 For all these reasons, the Centers for Disease Control and Prevention (CDC) has designated C. auris as the first fungal pathogen to pose a significant threat for global public health,11 and the World Health Organization (WHO) has included it in the critical priority group of the fungal priority pathogens list published recently.12

The risk factors for suffering from C. auris infection are similar to those found for C. albicans infections, namely immunosuppression, long hospitalization in Intensive Care Units, presence of central venous catheters or previous treatment with antibiotics or antifungal compounds.3 Moreover, due to the delay in making a correct diagnosis and the high resistance rates presented to mostly used antifungals,5C. auris infections present mortality rates of up to 60%,6 causing great concern in the healthcare system environment.

C. auris is composed of five different clades6,13 and it is phylogenetically close to the Candida haemulonii species complex.4 Its strains can also be classified into non-aggregative and aggregative growth phenotypes,14 which seems to have an impact on their capacity to form biofilms and on their virulence.15In vivo studies done in invertebrate models such as Galleria mellonella(14) or Caenorhabditis elegans(16) have shown greater virulence presented by non-aggregative strains with respect to the aggregative ones. To date, several studies of murine models of disseminated infections have been carried out in order to understand C. auris virulence17,18 and the immune response triggered on the host.19 However, there are no immunoproteomic studies that have investigated the most relevant C. auris antigens involved in systemic infections.

Due to that, the aim of this study is to identify the most immunoreactive antigens of C. auris. To achieve this, an immunocompetent murine model of disseminated infection was developed using both non-aggregative and aggregative isolates of C. auris, and the sera obtained were used to detect and identify the most immunoreactive antigens. In addition, the antigenicity of the spots identified with mice sera was analyzed by using sera from patients with disseminated C. auris infection and from mice infected with C. albicans and A. fumigatus. Therefore, this study provides valuable information about the infection process caused by both growth phenotypes of C. auris, as well as their most immunoreactive antigens, which may be important for the development of new diagnostic and therapeutic strategies.

Materials and Methods

Microorganisms and Human Sera

In this study, C. auris CECT (Spanish Culture Type Collection) 13225 (non-aggregative) and CECT 13226 (aggregative), C. albicans SC5314, and C. haemulonii CECT 11935 strains were used. C. auris isolates from bloodstream infections and sera from patients with disseminated C. auris were obtained from University and Polytechnic La Fe Hospital (Valencia, Spain). The Ethical Committees from the University of the Basque Country (UPV/EHU) (ref M30/2020/019) and from the University and Polytechnic La Fe Hospital (ref 2020-642-1) approved all the procedures.

All of the strains were cryopreserved at −80 °C and cultured on Sabouraud Dextrose Agar (SDA) (Condalab, Madrid, Spain) at 37 °C for 24 h before use. To obtain C. auris cells, yeasts were grown on SDA tubes at 37 °C for 24 h and they were resuspended in Dulbecco’s phosphate-buffered saline (DPBS) (Corning, New York, USA). The concentration was adjusted using a hemocytometer to inoculate 5 × 105 yeasts/mL in Sabouraud Dextrose Broth (SDB) (Millipore, Massachusetts, USA) and then they were incubated at 37 °C overnight at 120 rpm. Finally, fungal cells were collected by centrifugation (8100g, 3 min).

Models of Murine Disseminated Infection

Six to eight-week-old Swiss female mice bred and maintained at the SGIker Animal Facility of the UPV/EHU were used. Animals were maintained with water and food ad libitum in filter-aerated sterile cages. The Animal Experimentation Ethical Committee from the UPV/EHU approved all the procedures (ref M20/2020/034).

Mice were anesthetized by intraperitoneal injection of 100 mg/kg ketamine and 5 mg/kg xylazine. All infections were made by the intravenous injection of fungal cells suspended in 0.2 mL of DPBS in the tail vein of each animal.

For the development of the murine model of C. auris disseminated infection, 35 mice were divided into seven groups of five mice each. For each C. auris isolate, aggregative and non-aggregative, three doses were tested, 106, 107, and 5 × 107 yeasts/animal, each one given to a group of mice. The inoculum was verified by plating and counting serial dilutions of each infection dose on SDA plates. The last group was the control group, which was only injected with 0.2 mL of DPBS.

For the comparative study of the humoral response produced by both isolates of C. auris, C. haemulonii, and C. albicans yeasts, another 35 mice divided into five groups were used. Two of these groups, consisting of five mice each (to complete 10 mice for each C. auris isolate together with those used in the previous experiment) were intravenously injected with 5 × 107 yeasts/animal of non-aggregative or aggregative C. auris isolates. Another two groups, consisting of 10 mice each, were inoculated with 5 × 107 yeasts/animal of C. haemulonii and 105 yeasts/animal of C. albicans. The inoculum was verified by plating and counting serial dilutions of each infection dose on SDA plates. The last group was the control group, made of five mice injected with 0.2 mL of DPBS. Sera of mice infected with 5 × 106 conidia/animal of Aspergillus fumigatus was obtained from a previous assay done by our research group.20

Study of the Infection Process by CFU Counting and Histology

Twenty-eight days after the injection, mice were euthanized, and total blood as well as the brain, lungs, kidneys, spleen, and liver were extracted. Blood samples were coagulated and centrifuged (Microvette, Sarstedt, Nümbrecht, Germany). Obtained sera were stored at −80 °C until they were needed. Organs were divided into two halves; one was used for fungal load determination through colony forming unit (CFU) counting, and the other one for the histological study.

For the determination of the fungal load on the extracted organs, half of the organs were weighed and mechanically homogenized in 1 mL of DPBS. Then, 0.1 mL of the diluted sample was inoculated in duplicate by extension on SDA plates containing 10 μg/mL chloramphenicol (Sigma Aldrich, St Louis, Missouri, USA) and 25 μg/mL gentamicin (Sigma Aldrich). Plates were incubated at 37 °C and the CFUs were counted after 2–3 days. The limit of detection (LOD) was calculated as the minimum microbial density (log CFU/g) necessary in each organ to detect 1 CFU in the volume plated out. All data below the LOD, including 0 values, were censored at this limit.

To perform the histological study, the organs were fixed in 10% formalin and immersed in paraffin. Five μm thick sections were obtained in a microtome and adhered to previously albumin-coated microscopical slides and then dried at 37 °C overnight. For general observation a Haematoxylin–Eosin (HE) staining, as described by Martoja and Martoja-Pierson,21 was performed. In order to detect fungi in the tissues, Grocott Methenamine Silver (GMS) (Sigma Aldrich) staining, as described by Gomori,22 was carried out.

Obtaining Total Protein Extract of C. auris

To obtain the total protein extract of C. auris, 5 × 105 yeasts/mL were grown at 37 °C and 120 rpm in SDB for 24 h. Then, the culture was centrifuged at 2855g and 4 °C for 5 min and washed twice with phosphate-buffered saline (PBS). The cell pellets were resuspended in PBS with 1% (v/v) 2-mercaptoethanol and 1% (v/v) ampholites pH 3–10 (GE Healthcare, Freiburg, Germany), and lysed with crystal beads (0.5 mm diameter) at 28 Hz for 20 min using the Millmix 20 Bead-Beater (Thetnica, Eslovenia).

For each C. auris isolate, three different total protein extracts were obtained. Protein concentration was measured using the Pierce 660 nm protein assay reagent (Thermo Fisher Scientific, Waltham, Massachusetts, USA).

Protein Separation by Electrophoresis

The proteins of the extracts were precipitated following the method described by Pellon et al.23 Briefly, the precipitation of the total protein extract was achieved by adding four volumes of 10% trichloroacetic acid and 0.07% 2-mercaptoethanol in acetone, and the obtained protein pellet was dissolved in rehydration buffer (7 M Urea, 2 M thiourea, 4% (w/v) CHAPS, 20 mM Tris). Once fully dissolved, the samples were stored at −20 °C until use.

Protein separation was made by one-dimensional (1D) or two-dimensional (2D) electrophoresis. The 1D electrophoresis was carried out by loading 40 μg of protein to 10% acrylamide gels and running them at 70 mA, 100 W, and 200 V for 45 min in a Miniprotean II (Bio-Rad, Hercules, California, USA), using the Page Ruler Plus (Thermo Fisher Scientific) as the protein standard. For 2D electrophoresis, the method described by Pellon et al.23 was used, loading 800 μg of protein to 18 cm long Immobiline DryStrip gels (pH 3–10, GE Healthcare) for the isoelectric focusing (IEF), and using 10% acrylamide gels for the 2D. The gels were stained with Coomassie Brilliant Blue (CBB) and digitalized with ImageScanner III (GE Healthcare) software or transferred to membranes for antigenic detection. All the 1D and 2D were made in triplicate, and only the most informative gels are shown.

Antigenic Detection

Protein spots were transferred to Amersham Hybond-P poly(vinylidene difluoride) (PVDF) membranes (GE Healthcare) at 400 mA for 2 h and stained with Ponceau Red (0.2% (w/v) Ponceau Red, 1% (v/v) acetic acid) in order to confirm the correct transference of proteins. For antigen detection, Western Blot (WB) was performed. First, membranes were blocked in Tris-buffered saline (TBS) with 5% (w/v) skimmed milk and 0.1% (v/v) Tween 20 (TBSM) for 2 h and they were incubated overnight at 4 °C with mouse serum diluted to 1/1000 or human serum diluted to 1/200 in TBSM. After incubation, membranes were washed four times for 5 min with TBS. Murine or human anti-IgG-HPR diluted to 1/100 000 in TBSM was added and incubated for 30 min. Finally, membranes were washed four additional times for 5 min with TBS. All of the incubations were performed at room temperature (RT) and agitated, unless otherwise indicated. The detection of immunoreactive proteins was achieved using ECL Advanced (NZYTech, Lisbon, Portugal) following the manufacturer’s instructions in the G:BOX Chemi System (Syngene, Cambridge, UK). ImageMaster 2D Platinum Software (GE Healthcare) was used for the WB analysis.

When needed, the oxidation of the glycoproteins transferred to the PVDF membrane was achieved by 50 mM sodium metaperiodate treatment in 100 mM sodium acetate buffer (pH 5.5) at RT for 30 min. Then, the membrane was washed four times for 5 min with TBS and the WB process described above was followed.

Identification of Immunoreactive Proteins

The most immunoreactive antigens detected were manually extracted from CBB-stained gels and identified by LC-MS/MS in the SGIker proteomic services of the UPV/EHU, as described in Buldain et al.,24 with a few modifications. LC-MS/MS was carried out on Q Exactive HF-X or Exploris 240 mass spectrometers (Thermo Fisher Scientific) interfaced with the EASY nLC-1200 system (Thermo Fisher Scientific). The search for protein identification of the sequenced peptides was performed in the Uniprot database (https://www.uniprot.org/), restricted to C. auris. When more than one result was obtained for the same spot, the only proteins shown were the best-identified protein from that spot and those with a score greater than 60% of the data obtained for the best and with coverage greater than 10%. The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE25 partner repository with the data set identifier PXD049077.

Bioinformatic Analysis of C. auris Antigens

DeepLoc 2.0 (https://services.healthtech.dtu.dk/services/DeepLoc-2.0/), SignalP 6.0 (https://services.healthtech.dtu.dk/services/SignalP-6.0/), SecretomeP 2.0 (https://services.healthtech.dtu.dk/services/SecretomeP-2.0/), and FaaPred (https://bioinfo.icgeb.res.in/faap/query.html) were used to predict the location, the secretion through signal peptides or non-classical methods, and the possible adhesion properties of the antigens, respectively. On DeepLoc 2.0, the cellular location of the antigens was indicated. On the rest of the prediction pages, results were considered positive when the score was >0.5 for SignalP 6.0, >0.6 for SecretomeP 2.0, or setting a −0.8 threshold value for FaaPred. For the study of the functionality, family, and domains, the Interpro (https://www.ebi.ac.uk/interpro/) database was used. Besides, for the antigenicity and the protective antigen predictions, AntigenPRO (https://scratch.proteomics.ics.uci.edu/), and VaxiJen 2.0 (http://www.ddg-pharmfac.net/vaxijen/VaxiJen/VaxiJen.html) were used. AllerTOP v.2 (http://www.ddg-pharmfac.net/AllerTOP/) and AllergenFP (http://www.ddg-pharmfac.net/AllergenFP/) were chosen for the allergenicity prediction of the antigens. Finally, NCBI BlastP (https://blast.ncbi.nlm.nih.gov/Blast.cgi) was used for the study of the homology and the alignment of the proteins with other fungal species, as well as with humans.

Statistics

Statistical analyses were carried out using the ANOVA method followed by multiple comparisons corrected with Dunnett’s test in SPSS (version 26.0 for Windows, Chicago, Illinois, USA) and plotted using GraphPad Prism version 8 (GraphPad Prism Software Inc., San Diego, California, USA). Values of p < 0.05 were considered statistically significant.

Results

Determination of the Infective Dose of C. auris

The study of the different doses showed that as the dose increased, so did the fungal load in the kidneys and lungs of mice infected with each of the isolates, spleen of mice infected with the non-aggregative isolate, and the liver of mice infected with the aggregative isolate. However, the differences between the highest (5 × 107 yeasts/animal) and the lowest dose (106 yeasts/animal) were not statistically significant, except for the lungs of the mice infected with the non-aggregative isolate. Specifically, the kidneys, lungs, and spleen were the organs with the greatest fungal load, showing with the highest dose 4.09 ± 0.97, 1.87 ± 0.30, and 2.50 ± 0.93 log CFU/g, respectively, for the non-aggregative isolate and 5.24 ± 0.63, 2.31 ± 0.73, and 2.32 ± 0.47 log CFU/g, respectively, for the aggregative isolate (Figure 1A).

Figure 1.

Figure 1

Determination of the infective dose of C. auris non-aggregative and aggregative isolates on immunocompetent murine model of disseminated infection. Fungal tissue burdens of different inocula of C. auris non-aggregative or aggregative isolates (A), percentage of mice infected with 106, 107, and 5 × 107 yeasts/animal of the non-aggregative (B) and the aggregative (C) isolate that presented neurological alterations and weekly weight monitoring of mice inoculated with 106, 107, and 5 × 107 yeasts/animal of non-aggregative (D) and aggregative (E) C. auris are shown. The limit of detection (LOD) for each organ is indicated. All data below the LOD, including 0 values, were censored at this limit. *p < 0.05, **p < 0.01.

Signs indicative of infection (Table S1) were detected only for the highest inoculum dose. Among them, neurological alterations such as head bobbing and leaning to one side were the most common, but ruffled hair, curved abdomen, stereotypies, and weight loss were also detected. Specifically, neurological alterations were the most frequently observed symptoms. They were observed in 60% and 50% of the mice infected with the highest infective dose of the non-aggregative and aggregative C. auris isolates, respectively. In the case of the non-aggregative strain, no symptoms were observed with the lower doses, whereas in the case of the aggregative strain, the symptoms observed with the highest dose were detected some days earlier than with lower doses (Figure 1B,C). Similarly, weight loss, or more specifically, the absence of weight gain compared to the mice inoculated with the rest of the doses, was observed with a dose of 5 × 107 yeasts/animal for either isolate (Figure 1D,E). Regarding mice survival, no mortality was found with either of the C. auris isolates. Therefore, due to the higher fungal load, greater weight loss, and higher frequency of neurological alterations presented, the dose of 5 × 107 yeasts/animal was selected as the infective dose.

Comparative Study of Disseminated Murine Infections Caused by Non-aggregative and Aggregative C. auris Isolates

After the infection of five additional mice to complete groups of 10 individuals with each of the growth phenotypes of C. auris, the differences between the infections caused by each of the isolates were studied by histological analysis of different organs, the determination of the fungal load, the appearance of the neurological symptoms, and the evolution of the weight of the infected animals.

The histological study of the kidneys using HE staining showed that whereas no alterations were detected in mice inoculated with DPBS (Figure 2A,D) or the aggregative isolate (2C, 2F), significant histological damages were observed in the kidneys of mice exposed to the non-aggregative C. auris (Figure 2B,E). Most notably, there was clear evidence of characteristic granulomatous inflammation with important cellular infiltration (Figure 2B) and severe structural alterations in both kidney tubules and glomeruli (Figure 2E). Moreover, GMS staining showed fungal particles as dark silver precipitates mainly detected in the tubular epithelium of the kidneys, and these were also more abundant in the kidneys exposed to the non-aggregative (Figure 2H) than to the aggregative C. auris (Figure 2I). The low amounts of aggregative C. auris yeasts visualized in the histological study seem not to be in agreement with the CFU data of the kidneys. However, we hypothesize that the aggregative phenotype could result in a non-homogeneous distribution of the isolate, making the histological analysis more challenging.

Figure 2.

Figure 2

Microscopical images of Hematoxylin-Eosin-stained (A–F and J–L) and Gomori Methenamine Silver-stained (G–I and M–O) mouse kidneys and brain infected with 5 × 107 yeasts/animal. Control (A, D, G, J, and M), non-aggregative (B, E, H, K, and N) and aggregative (C, F, I, L, and O) C. auris exposed mouse kidneys and brain. Note the relevant immune response induced in the C. auris non-aggregative isolate exposed animal kidneys, delimited by the dotted black line (B) and the more limited response in the aggregative C. auris isolate (C; black triangles). Note also the relevant immune response induced in the non-aggregative C. auris exposed animal kidneys with altered tubule and glomeruli structures (E; red triangles). The presence of fungi was detected in the kidney tubule epithelium after Gomori staining as a dark brown-black deposit (H and I; white triangles), very relevant in C. auris non-aggregative isolate (H), much more limited in C. auris aggregative isolate (I) and without signal in the control group (G). Note the limited presence of fungi (N and O; white triangles) in the non-aggregative (N) and aggregative (O) exposed brains of mice. Some unspecific silver staining in the heterochromatin of nuclei (M, N, and O; blue triangles) was also observed. Scale bar = 200 μm (A–C), 100 μm (D–F and J–L), and 10 μm (G–I and M–O).

On the other hand, the histological study of the brain and cerebellum structure performed by HE staining did not reveal significant differences between the mice infected with each isolate (Figure 2K,L), as they presented similar characteristics to the brain of mice inoculated with DPBS (Figure 2J). Furthermore, almost no reaction was observed by GMS staining in the brain samples of mice infected with either C. auris isolate, detecting only a very low number of yeasts in the brains of the animals (Figure 2N,O).

With respect to the comparison between the fungal burdens caused by each of the growth phenotypes of C. auris, no statistically significant differences were found in the organs analyzed (Figure 3A). Signs of infection were more frequently observed in the group of mice infected with the non-aggregative isolate, neurological alterations being present in 70% and 50% of the mice infected with non-aggregative and aggregative isolates, respectively (Figure 3B). Besides, the median time of appearance of the neurological symptoms for the mice infected with the non-aggregative or aggregative C. auris isolates were 13 and 27.5 days, respectively. This different trend between the infections caused by each growth phenotype was also observed in the evolution of the weight, since at 28 days postinfection mice inoculated with the non-aggregative isolate showed 99.90% of the initial weight, whereas those infected with the aggregative isolate showed 107.97% (Figure 3C).

Figure 3.

Figure 3

Comparative study of disseminated murine infections caused by 5 × 107 yeasts/animal of non-aggregative and aggregative C. auris isolates, 5 × 107 yeasts/animal of C. haemulonii and 105 yeasts/animal of C. albicans. Fungal tissue burdens (A), where mice infected with C. albicans and euthanized are indicated as red triangles, percentage of mice that presented neurological alterations (B) and weekly weight monitoring of the mice (C) are shown. The limit of detection (LOD) for each organ is indicated. All data below the LOD, including 0 values, were censored at this limit. *p < 0.05, **p < 0.01, and ***p < 0.001.

Comparative Study of Disseminated Murine Infections Caused by C. auris, C. haemulonii, and C. albicans

The comparison between the infections caused by the three different Candida species showed that, although no mortality was found in the groups infected with C. auris or C. haemulonii, 60% of the mice infected with C. albicans reached the humane end-point before the end of the experiment, most frequently showing symptoms such as a decrease of more than 25% of the initial weight, persistent lethargy, and body stretching. In general, ruffled hair and weight loss were noticed as signs of C. albicans infection, similar to what was observed with C. auris infection, but only one mouse presented neurological alterations (Figure 3B). Finally, in mice inoculated with C. haemulonii only a few mice showed ruffled hair temporally, not being a permanent symptom of an ongoing infection.

On the other hand, the mice surviving 28 days after C. albicans injection were able to clear the yeast from almost all organs. However, in mice sacrificed due to deteriorating health, a greater fungal load was observed in almost all the analyzed organs. Concerning interspecies comparison, no significant differences were found between the groups of mice infected with C. auris or C. albicans, except for the brain, where a significantly higher amount of CFU/g was recovered from the group infected with C. albicans than those infected with each C. auris isolate. In the case of C. haemulonii, no CFUs were detected in any organ of six out of the ten mice inoculated. Actually, only in one kidney, one spleen, and one liver, a number of CFUs above the LOD, but close to it, were counted (Figure 3A).

The weight loss suffered and the subsequent weight recovery was similar in the animals infected with C. albicans and those infected with the non-aggregative C. auris isolate (Figure 3C). No weight loss was recorded in mice infected with C. haemulonii, the evolution of the weight being similar to that obtained with the control group, reaching 112.43% of the initial weight at 28 days postinfection.

Identification of the Most Immunoreactive Antigens of the Total Extract of C. auris

Sera obtained from the mice infected with each C. auris isolate were used to identify the most immunoreactive antigens of the total protein extract of the yeast by WB. First, it was confirmed that all the mice developed an adequate humoral response by challenging sera obtained from each infected mouse individually with non-aggregative C. auris total protein extract (Figure S1). The results showed that all sera from infected mice presented reactivity against C. auris, while no reactivity was found in those from the control mice.

After that, the total protein extract of the non-aggregative and aggregative C. auris isolates were separated by 2D electrophoresis and CBB stained, showing 395 ± 100.71 and 483 ± 56.96 spots, respectively. In both proteomes, the majority of the protein spots were localized within the ranges of 4.5–7.5 pI and 20–100 kDa values (Figure 4A,D). Then, pools of sera from the control, non-aggregative (Figure 4B,E), and aggregative (Figure 4C,F) C. auris-infected groups were used to study their immunoreactivity against the proteome of each growth phenotype by WB.

Figure 4.

Figure 4

2D-WB images of the proteome and immunomes of C. auris non-aggregative (A–C) and aggregative (D–F) isolates. The proteome of each growth phenotype was challenged with the pooled sera obtained from mice with disseminated candidiasis caused by C. auris non-aggregative isolate (B and E) and the pooled sera obtained from mice with disseminated candidiasis caused by C. auris aggregative isolate (C and F). Mice were infected with 5 × 107 yeasts/animal of non-aggregative or aggregative C. auris. The identified spots are marked with red arrows.

As expected, no reactivity was observed using sera from the control group (data not shown). Regarding C. auris-infected mice, using the pooled sera from the animals infected with the non-aggregative isolate it was impossible to discriminate between the protein extracts of the two fungal isolates, showing the same recognition pattern for both proteomes (Figure 4B,E). The same happened when the sera from the animals infected with the aggregative isolate were tested (Figure 4C,F). However, there were differences in the intensity and the number of antigens recognized between the two pools of sera. The pool of sera collected from mice infected with the aggregative C. auris isolate displayed less reactivity and detected fewer antigenic spots compared to the sera from mice inoculated with the non-aggregative isolate. Specifically, 60 ± 26.81 and 138 ± 15.87 immunoreactive spots were detected, respectively. In fact, the antigenicity pattern exhibited by these sera pools showed the majority of the spots in an area located within the ranges of 4.5–7.5 pI and 20–55 kDa, but on certain low molecular weight antigens (20–35 kDa) almost no reactivity was observed when sera pools from aggregative C. auris infections were used.

Once the immunomes were analyzed, 13 immunoreactive spots recognized by both pools of sera from infected mice in the two C. auris extracts were identified by LC-MS/MS (Table 1). The analysis included the 10 most immunoreactive spots (%vol) of both immunomes, as well as the three spots detected most intensively by sera from mice infected with the non-aggregative isolate on the differentially recognized low molecular weight (20–35 kDa) segment of the proteome.

Table 1. Identification by LC-MS/MS of the Most Immunoreactive Antigens of C. auris Commonly Detected in Both Proteomes by Both Pools of Sera Useda.

spot number uniprot number name of the protein unique peptides cover (%) score theoretical pI/Mr (kDa) experimental pI/Mr (kDa) %vol
1 A0A5C1DTP2 phosphopyruvate hydratase 22 60 162.47 5.67/47.1 4.94/50.66 3
2 A0A5C1DTP2 phosphopyruvate hydratase 20 46 211 5.67/47.1 5.11/49.46 3.24
3 A0A5C1DTP2 phosphopyruvate hydratase 21 49 245.48 5.67/47.1 5.26/48.87 5.25
4 A0A2H1A7F9 phosphopyruvate hydratase 28 57 1170.69 5.67/47.1 5.51/48.4 10.18
5 A0A5Q7YAC2 phosphoglycerate kinase 26 60 188.4 6.83/44.4 6.6/44.51 3.85
6 A0A5Q7YAC2 phosphoglycerate kinase 22 52 187.13 6.83/44.4 7/44.51 5.98
7 A0A2H0ZYR1 phosphoglycerate kinase 30 68 814.25 6.83/44.4 7.63/45.08 9.76
8 A0A5Q7YEJ9 glyceraldehyde-3-phosphate dehydrogenase 12 33 123.08 7.09/35.3 6.48/37.1 3.2
9 A0A5Q7YEJ9 glyceraldehyde-3-phosphate dehydrogenase 12 32 130.72 7.09/35.3 6.82/37.43 4.98
10 A0A5Q7YEJ9 glyceraldehyde-3-phosphate dehydrogenase 12 36 250.46 7.09/35.3 7.26/37.27 4.14
11 A0A5Q7YEJ9 glyceraldehyde-3-phosphate dehydrogenase 7 22 105.48 7.09/35.3 6.76/24.70 1.85
12 A0A5Q7YEJ9 glyceraldehyde-3-phosphate dehydrogenase 5 18 33.7 7.09/35.3 6.33/24.15 1.25
13 A0A5Q7YEJ9 glyceraldehyde-3-phosphate dehydrogenase 4 15 22.18 7.09/35.3 7.97/26.68 1.07
A0A510PAL8 phosphoglycerate mutase 4 13 17.85 6.96/27.6
A0A5Q7YAC2 phosphoglycerate kinase 7 14 15.43 6.83/44.4
a

Information about Uniprot number, name of the protein, unique peptides identified, identified coverage, score of the identification, theoretical and experimental pI and Mr (kDa) values, and %vol of the antigenic spots are provided.

The results from LC-MS/MS showed that the 13 spots corresponded to four proteins, phosphopyruvate hydratase or enolase (Eno), phosphoglycerate kinase (Pgk), glyceraldehyde-3-phosphate dehydrogenase (Gapdh), and phosphoglycerate mutase (Pgm). As expected, the spots with the same Mr and similar pI seemed to be isoforms of the same protein. In addition, Gapdh was also identified in the three antigenic spots with lower molecular weights, which might correspond to different fragments of the protein.

Bioinformatic Analysis of C. auris Antigens

The bioinformatic analysis conducted to investigate the characteristics of the identified proteins showed that all of them were localized in the cytoplasm (Figure 5A), except for Eno, which can also be found in the nucleus. None of the antigens were predicted to be secreted by conventional or non-conventional pathways. Furthermore, Gapdh and Pgm showed adhesion properties. On the other hand, the four proteins identified were predicted as antigenic and protective antigens for alternative therapeutic strategies, and two of them, Eno and Pgk, are probable allergens (Figure 5B).

Figure 5.

Figure 5

Bioinformatics analysis and study of the functionality of C. auris most immunoreactive antigens identified by LC-MS/MS. The localization of the identified proteins (A), their antigenicity, protective antigen capacity and allergenicity (B) and their homology with corresponding C. haemulonii, C. albicans, A. fumigatus, and human proteins (C) are shown. Involvement of the identified proteins in the biological processes (D), cellular components (E), and molecular functions (F) are indicated.

The analysis of protein sequence homology between these C. auris proteins and those of C. haemulonii, C. albicans, A. fumigatus, and humans revealed that, as expected, the greatest similarities were found with C. haemulonii and the least similarities with A. fumigatus and humans (Figure 5C). More specifically, Eno and Pgk are the proteins with the highest similarity percentages among all the organisms tested (>60%), and Pgm presents the lowest similarities when compared with A. fumigatus and human proteins (23% and 52%, respectively).

According to the study of the functionality, the four proteins identified are involved in metabolic or cellular processes, and all of them participate in the carbohydrate metabolic process. The Gapdh is implicated specifically on the glucose metabolic process and the other three proteins on the glycolytic process (Figure 5D). Moreover, only Eno is a constituent of the cellular component, participating in both the protein-containing complex and the cellular anatomical entity (Figure 5E). Finally, with respect to the molecular function, these four proteins are involved in catalytic and binding activities, such as transferase, mutase, oxidoreductase, kinase, and hydratase activities (Figure 5F).

Study of the Humoral Response of Mice Infected with C. haemulonii, C. albicans, and A. fumigatus and from Patients with Disseminated Infection Caused by C. auris

To determine the specificity of the identified antigens, sera obtained from mice with disseminated infections caused by C. haemulonii, C. albicans, and A. fumigatus were used against the proteome of C. auris. Of the Candida species, C. haemulonii was selected because it is the most closely related species of the genera based on phylogeny, and C. albicans because it is the primary cause of invasive candidiasis. Additionally, A. fumigatus was selected among filamentous fungi, since it is the most commonly isolated filamentous fungal species from invasive fungal infections.

Since the proteomes obtained from both growth phenotypes of C. auris were similar, and the non-aggregative phenotype is the most frequently isolated in candidemia cases and described as more virulent than the aggregative phenotype,26 only that of the non-aggregative isolate was used for the following immunoproteomic studies. First, the reactivity of sera obtained from C. haemulonii and C. albicans infected mice was individually evaluated by 1D-WB (Figure S2). The sera from mice infected with C. haemulonii showed almost no reactivity against the protein extract of the non-aggregative C. auris (Figure S2A), and only three out of ten mice showed very low reactivity against the C. haemulonii extract (Figure S2B). Similarly, when the non-aggregative C. auris proteome was challenged with sera from C. albicans infected mice almost no reactivity was observed (Figure S2A). However, all of these sera showed reactivity to some extent when tested against the C. albicans protein extract, obtaining the greatest intensities in the case of the sera from the four mice that survived 28 days postinfection (Figure S2C). Due to the low reactivity observed for the sera of C. haemulonii, they were not used in the following comparative study of the humoral response.

The immunoproteomics study of the specific humoral response of mice infected with C. auris, C. albicans, and A. fumigatus (Figure 6B–D) against the protein extract of the non-aggregative C. auris isolate revealed that the 13 antigens identified as the most immunoreactive of C. auris were specific to this species, as they were not detected by sera from mice infected with C. albicans (Figure 6C) and A. fumigatus (Figure 6D). The antigenic spots recognized by C. albicans were not detected among the most immunoreactive against sera from C. auris infections, and the only spot detected by sera obtained from A. fumigatus infections was not detected by sera from C. auris infection.

Figure 6.

Figure 6

2D-WB images of the proteome and immunome of non-aggregative C. auris isolate. The proteome of the non-aggregative phenotype (A) was challenged with the pooled sera obtained from mice with disseminated candidiasis caused by non-aggregative C. auris (B) and C. albicans (C), disseminated aspergillosis caused by A. fumigatus (D) and of patients with disseminated infection caused by C. auris, without (E) and with deglycosylation (F) of the glycoproteins. Pools of sera of mice infected with 5 × 107 yeasts/animal of non-aggregative C. auris, 105 yeasts/animal of C. albicans and 5 × 106 conidia/animal of A. fumigatus were used.

Finally, a pool of five sera obtained from human patients with disseminated C. auris infection was used to corroborate the results observed in the mice model used (Figure 6E,F). The performed 2D-WB analysis with this sera pool showed high reactivity mainly located on the high molecular weight and acidic pI. This diffuse signal detected was probably due to the glycoproteins of C. auris, and they may interfere with the clear visualization of the nonglycosylated antigenic spots (Figure 6E). Therefore, glycoproteins were oxidized using sodium metaperiodate and, in this way, the immunome observed using the pool of sera from patients with disseminated C. auris infection (Figure 6F) had a similar recognition pattern to that observed with the sera obtained from mice infected with the non-aggregative C. auris. In addition, all of the antigens identified in this study as the most immunoreactive of C. auris by using the mouse model of disseminated C. auris infection seemed to be also recognized by infected human sera, which would confirm the validity of the disseminated murine infection model developed.

Discussion

Currently, there is a need for novel diagnostic and therapeutic approaches to enhance the prognosis of the infections caused by C. auris. In this study, we aimed to address this need by establishing an immunocompetent murine model of disseminated C. auris infection with one isolate of each growth phenotype, non-aggregative or aggregative, to obtain sera to identify their most immunoreactive antigens. Moreover, the infection was compared to that caused by C. albicans and C. haemulonii, and the immunoreactivity of the C. auris antigens was also studied using sera obtained from murine disseminated infections caused by C. albicans and A. fumigatus, and with pools of sera obtained from human patients with disseminated infection caused by C. auris.

First, the 5 × 107 yeasts/animal dose of C. auris was selected as the infective dose capable of generating disseminated infections. In agreement with other studies with immunocompetent mice infected with C. auris, no mortality was found.2729 Moreover, no statistical differences were found in the fungal load between the lowest and the highest doses in the majority of the organs studied, as reported by Wang et al.,29 hypothesizing that this could be due to the lower activation of the innate immune response triggered by C. auris compared to C. albicans. However, only the animals infected with the highest dose of both growth phenotypes suffered signs of disease such as weight loss during the infection process and neurological alterations as previously observed,28,29 which could be linked to brain edema.28

Regarding the comparison between the infections caused by both growth phenotypes, our results showed higher virulence, in terms of infection signs and weight evolution, in the non-aggregative isolate, as reported in previous studies of murine30,31 and Galleria mellonella infections.14,15,32 In addition, the higher virulence of the non-aggregative isolate was also confirmed by the histological study, since it showed important alterations in the tubular and glomerular structures of the kidney and a higher induced immune response than that observed with the aggregative isolate. Despite the fact that a worse recognition of the cellular aggregates had been previously suggested by Ben-Ami et al.17 and that in our study the fungal load was generally slightly higher in the mice infected with the aggregative than with the non-aggregative C. auris isolate, no statistically significant differences were found.

The comparison of C. auris infections with C. albicans and C. haemulonii showed a higher mortality rate in C. albicans, whereas no mortality was reported for C. auris or C. haemulonii, as in previous studies.17,27,30,33,34 Although no significant differences could be found between the fungal load presented by C. auris and C. albicans in the majority of the organs, more CFUs were detected in the brain of C. albicans infected mice than on mice infected with each C. auris isolate, as reported by Wang et al.27 Nevertheless, in C. albicans infected mice few neurological alterations were found, whereas in the mice infected with both isolates of C. auris they were one of the most frequent symptoms. This could be because mice infected with C. albicans died before the onset of symptoms, or because the enhanced immune system response to this species29 prevented the appearance of these neurological signs. In fact, the mice infected with C. albicans that reached the end of the experiment were able to clear almost completely the yeasts from their bodies. This could also explain the weight gain of this group in comparison to the one infected with the non-aggregative isolate of C. auris, as some mice were sacrificed due to worsening conditions and only the ones presenting the strongest immune response reached the end-point of the experiment.

On the other hand, in the immunoproteomics-based study performed with sera from the mice infected with each C. auris isolate, 13 spots recognized by both pools of sera were identified, corresponding to four proteins: Eno, Pgk, Gapdh, and Pgm. These proteins were also detected by Pitarch et al.35,36 as relevant cytoplasmic and cell wall antigens of C. albicans. The most remarkable results from the bioinformatics analysis of their sequence are that Gapdh and Pgm showed adhesion properties, which can facilitate the fungus–host interaction and the invasion of the host, as observed with other yeasts such as Paracoccidioides brasilensis and C. albicans.3739 As expected, higher homology values were observed with C. haemulonii proteins, since this species is phylogenetically closer than C. albicans.4 The study of the functionality showed that the four identified proteins were involved in the carbohydrate metabolism process, this being relevant as it has been proven that C. auris escapes and kills macrophages by adapting its glycolytic capacity and depleting the glucose from the macrophages.40

Among these proteins, Eno is a well-known antigen in various fungal species such as filamentous fungi like Lomentospora prolificans(20,23) and A. fumigatus(41) or yeasts like Paracoccidioides lutzii(42) and C. albicans.35,36 Moreover, it is also found on the cell surface and even secreted43 and, in both locations, this protein is involved in interactions with the host and colonization.44,45 In addition to being used for diagnosis,46,47 the use of anti-Eno antibodies and recombinant Eno for passive or active immunization in mice has been studied, proving a moderate protection toward C. albicans induced candidiasis.4850

Pgk can also be found on the cell wall of C. albicans(36) and it has been reported as an antigen recognized by human salivary IgA from healthy immunocompetent individuals.51 This enzyme has also been studied for mice immunization against C. albicans and C. glabrata(52) and as a serological diagnostic marker.46 Specifically with C. auris, Rosario-Colon et. al.31 evaluated the protective capacity of monoclonal antibodies developed against Pgk in mice, which enhanced the survival of treated mice.

Gapdh is located both in the cytoplasm and as a surface antigen in C. albicans(53,54) and in L. prolificans secretome, cell surface and hyphae.20,23 This protein is also important for the evasion of the host immune system by high affinity binding to regulators of complement activation such as Factor H (FH) or FH-like protein (FHL-1).55 Due to this, Gil et al.56 assessed, unsuccessfully, the use of anti-Gapdh antibodies to protect mice from C. albicans systemic infection.

The last protein identified, Pgm, in addition to being an antigen in C. albicans disseminated infection,35,36,57 is a protein with protective immune capacity in Toxoplasma gondii infected mice.58 This protein has also been described in C. albicans cell surface and it is capable of binding to plasminogen, FH55,59 and the salivary agglutinin gp-340, important for oral microbial adherence.60 This protein has also been related to the virulence of the yeast,61 and showed the lowest homology among all the organisms tested, with values of 23% and 52% for A. fumigatus and human homologue proteins, respectively. This could be of special interest, as it could be a potential target for diagnostic or treatment options since the chances of side effects or cross-reactivity would be lower.

The immunoproteomics results also showed that the extracts from the two C. auris isolates were very similar. Moreover, the comparative study of the humoral responses induced by C. albicans and A. fumigatus against the proteome of non-aggregative C. auris isolate showed the specificity of the four identified antigens. This contradicts the antigenicity detected for these four proteins in C. albicans by Pitarch et al.35 when using sera obtained from mice infected with the same species. However, it could be related to the alteration of the structural epitopes of the proteins responsible for generating specific immune responses in the two Candida species, as demonstrated by the sequence variability observed in the bioinformatics analysis done. In fact, in our work, different antigenic spots as well as signal intensity were observed when C. albicans-infected mice sera were used against C. auris or C. albicans protein extracts. Moreover, the bioinformatics analysis of WBs after protein deglycosilation showed that sera from patients with invasive C. auris seemed to recognize the same antigenic pattern as sera from mice. Therefore, further research would be recommended to confirm it due to the difficulty in analyzing the diffuse signal acquired. Thus, the identified proteins could be potential targets for the specific detection of disseminated C. auris infections or for immunological treatment options.

In conclusion, the immunoreactive antigens Eno, Pgk, Gapdh, and Pgm, showed specificity toward C. auris and, therefore, they could be considered as candidates to be further studied as new promising diagnostic or even therapeutic targets for C. auris.

Acknowledgments

Animal experimentation and mass spectrometry analysis were performed at the Animal Facility and at the Proteomics Core Facility (member of ProteoRed-ISCIII) of the SGIker (UPV/EHU, ERDF, EU).

Glossary

Abbreviations

1D

one-dimensional

2D

two-dimensional

CBB

Coomassie brilliant blue

CDC

Centers for Disease Control and Prevention

CFU

colony forming unit

DPBS

Dulbecco’s phosphate-buffered saline

Eno

enolase

Gapdh

glyceraldehyde-3-phosphate dehydrogenase

GMS

grocott methenamine silver

HE

haematoxylin–eosin

IEF

isoelectric focusing

LOD

limit of detection

LC-MS/MS

liquid chromatography with tandem mass spectrometry

PBS

phosphate-buffered saline

Pgk

phosphoglycerate kinase

Pgm

phosphoglycerate mutase

PVDF

poly(vinylidene fluoride)

RT

room temperature

SDA

sabouraud dextrose agar

SDB

sabouraud dextrose broth

SDS-PAGE

sodium dodecyl-sulfate poly(acrylamide gel electrophoresis)

TBS

Tris-buffered saline

TBSM

Tris-buffered saline with skimmed milk

UPV/EHU

University of the Basque Country (UPV/EHU)

WB

western blot

WHO

World Health Organization

Data Availability Statement

The raw MS data associated with this manuscript was submitted to the ProteomeXChange database and is available under the identifier PXD049077.

Supporting Information Available

The Supporting Information is available free of charge at https://pubs.acs.org/doi/10.1021/acs.jproteome.3c00752.

  • Scoring system used during the supervision of mice in order to determine the relevant symptoms and their severity (Table S1); 1D-WB image of the reactivity shown by each mouse individually toward non-aggregative C. auris total extract proteins (Figure S1); 1D-WB images showing reactivity of each mouse infected with 5 × 107 yeasts/animal of C. haemulonii and 105 yeasts/animal of C. albicans (Figure S2); uncropped immunoblot images of this study (Figure S3) (PDF)

Author Contributions

M.A., O.R.-E., L.A.-F., and L.M.-S. carried out the proteomics experiments, and M.A., A.A., I.B., and A.Ra.-Ga. performed the experiments with mice. M.A. and B.Z. accomplished the histological study. A.Ru.-Ga. and J.P. obtained the C. auris isolates and the sera from human patients. A.A., A.R., and A.Ra.-Ga. conceived the experiments and supervised the work. M.A., A.A., and A.Ra.-Ga. wrote the manuscript. All authors have actively contributed in reviewing the manuscript and gave approval to the final version.

This research was funded by the Basque Government, grant number numbers IT1362-19 and IT1657-22. M.A., O.R.-E., and L.M.-S. have received a predoctoral grant from the Basque Government and L.A.-F. from the University of the Basque Country (UPV/EHU).

The authors declare no competing financial interest.

Supplementary Material

pr3c00752_si_001.pdf (1.1MB, pdf)

References

  1. Magill S. S.; Edwards J. R.; Bamberg W.; Beldavs Z. G.; Dumyati G.; Kainer M. A.; Lynfield R.; Maloney M.; McAllister-Hollod L.; Nadle J.; Ray S. M.; Thompson D. L.; Wilson L. E.; Fridkin S. K. Multistate Point-Prevalence Survey of Health Care–Associated Infections. N. Engl. J. Med. 2014, 370 (13), 1198–1208. 10.1056/NEJMoa1306801. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Schroeder M.; Weber T.; Denker T.; Winterland S.; Wichmann D.; Rohde H.; Ozga A. K.; Fischer M.; Kluge S. Epidemiology, Clinical Characteristics, and Outcome of Candidemia in Critically Ill Patients in Germany: A Single-Center Retrospective 10-Year Analysis. Ann. Intensive Care 2020, 10 (1), 142. 10.1186/s13613-020-00755-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Du H.; Bing J.; Hu T.; Ennis C. L.; Nobile C. J.; Huang G. Candida auris: Epidemiology, Biology, Antifungal Resistance, and Virulence. PLoS Pathog. 2020, 16 (10), e1008921. 10.1371/journal.ppat.1008921. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Satoh K.; Makimura K.; Hasumi Y.; Nishiyama Y.; Uchida K.; Yamaguchi H. Candida auris Sp. Nov., a Novel Ascomycetous Yeast Isolated from the External Ear Canal of an Inpatient in a Japanese Hospital. Microbiol. Immunol. 2009, 53 (1), 41–44. 10.1111/j.1348-0421.2008.00083.x. [DOI] [PubMed] [Google Scholar]
  5. Chowdhary A.; Prakash A.; Sharma C.; Kordalewska M.; Kumar A.; Sarma S.; Tarai B.; Singh A.; Upadhyaya G.; Upadhyay S.; Yadav P.; Singh P. K.; Khillan V.; Sachdeva N.; Perlin D. S.; Meis J. F. A Multicentre Study of Antifungal Susceptibility Patterns among 350 Candida auris Isolates (2009–17) in India: Role of the ERG11 and FKS1 Genes in Azole and Echinocandin Resistance. J. Antimicrob. Chemother. 2018, 73 (4), 891–899. 10.1093/jac/dkx480. [DOI] [PubMed] [Google Scholar]
  6. Lockhart S. R.; Etienne K. A.; Vallabhaneni S.; Farooqi J.; Chowdhary A.; Govender N. P.; Colombo A. L.; Calvo B.; Cuomo C. A.; Desjardins C. A.; Berkow E. L.; Castanheira M.; Magobo R. E.; Jabeen K.; Asghar R. J.; Meis J. F.; Jackson B.; Chiller T.; Litvintseva A. P. Simultaneous Emergence of Multidrug-Resistant Candida auris on 3 Continents Confirmed by Whole-Genome Sequencing and Epidemiological Analyses. Clin. Infect. Dis. 2017, 64 (2), 134–140. 10.1093/cid/ciw691. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Kathuria S.; Singh P. K.; Sharma C.; Prakash A.; Masih A.; Kumar A.; Meis J. F.; Chowdhary A. Multidrug-Resistant Candida auris Misidentified as Candida haemulonii: Characterization by Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry and DNA Sequencing and Its Antifungal Susceptibility Profile Variability by Vitek 2, CL. J. Clin. Microbiol. 2015, 53 (6), 1823–1830. 10.1128/JCM.00367-15. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Ku T. S. N.; Walraven C. J.; Lee S. A. Candida auris: Disinfectants and Implications for Infection Control. Front. Microbiol. 2018, 9, 357170. 10.3389/fmicb.2018.00726. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Ruiz-Gaitán A.; Martínez H.; Moret A. M.; Calabuig E.; Tasias M.; Alastruey-Izquierdo A.; Zaragoza Ó.; Mollar J.; Frasquet J.; Salavert-Lletí M.; Ramírez P.; López-Hontangas J. L.; Pemán J. Detection and Treatment of Candida auris in an Outbreak Situation: Risk Factors for Developing Colonization and Candidemia by This New Species in Critically Ill Patients. Expert Rev. Anti-Infect. Ther. 2019, 17 (4), 295–305. 10.1080/14787210.2019.1592675. [DOI] [PubMed] [Google Scholar]
  10. Sathyapalan D. T.; Antony R.; Nampoothiri V.; Kumar A.; Shashindran N.; James J.; Thomas J.; Prasanna P.; Sudhir A. S.; Philip J. M.; Edathadathil F.; Prabhu B.; Singh S.; Moni M. Evaluating the Measures Taken to Contain a Candida auris Outbreak in a Tertiary Care Hospital in South India: An Outbreak Investigational Study. BMC Infect. Dis. 2021, 21 (1), 425. 10.1186/s12879-021-06131-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. CDC . Clinical Alert to U.S. Healthcare Facilities - June 2016.
  12. Coordination G.; Alastruey-Izquierdo A.; World Health Organization . WHO Fungal Priority Pathogens List to Guide Research, Development and Public Health Action World Health Organization (WHO) 2022.
  13. Spruijtenburg B.; Badali H.; Abastabar M.; Mirhendi H.; Khodavaisy S.; Sharifisooraki J.; Taghizadeh Armaki M.; de Groot T.; Meis J. F. Confirmation of Fifth Candida auris Clade by Whole Genome Sequencing. Emerging Microbes Infect. 2022, 11 (1), 2405–2411. 10.1080/22221751.2022.2125349. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Borman A. M.; Szekely A.; Johnson E. M. Comparative Pathogenicity of United Kingdom Isolates of the Emerging Pathogen Candida auris and Other Key Pathogenic Candida Species. mSphere 2016, 1 (4), 10–1128. 10.1128/mSphere.00189-16. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Sherry L.; Ramage G.; Kean R.; Borman A.; Johnson E. M.; Richardson M. D.; Rautemaa-Richardson R. Biofilm-Forming Capability of Highly Virulent, Multidrug-Resistant Candida auris. Emerging Infect. Dis. 2017, 23 (2), 328–331. 10.3201/eid2302.161320. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Hernando-Ortiz A.; Mateo E.; Perez-Rodriguez A.; de Groot P. W. J.; Quindós G.; Eraso E. Virulence of Candida auris from Different Clinical Origins in Caenorhabditis elegans and Galleria mellonella Host Models. Virulence 2021, 12 (1), 1063–1075. 10.1080/21505594.2021.1908765. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Ben-Ami R.; Berman J.; Novikov A.; Bash E.; Shachor-Meyouhas Y.; Zakin S.; Maor Y.; Tarabia J.; Schechner V.; Adler A.; Finn T. Multidrug-Resistant Candida haemulonii and Candida auris, Tel Aviv, Israel. Emerging Infect. Dis. 2017, 23 (2), 195–203. 10.3201/eid2302.161486. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Muñoz J. E.; Ramirez L. M.; Dias L. S.; Rivas L. A.; Ramos L. S.; Santos A. L. S.; Taborda C. P.; Parra-Giraldo C. M. Pathogenicity Levels of Colombian Strains of Candida auris and Brazilian Strains of Candida haemulonii Species Complex in Both Murine and Galleria mellonella Experimental Models. J. Fungi 2020, 6 (3), 104. 10.3390/jof6030104. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Wurster S.; Albert N. D.; Kontoyiannis D. P. Candida auris Bloodstream Infection Induces Upregulation of the PD-1/PD-L1 Immune Checkpoint Pathway in an Immunocompetent Mouse Model. mSphere 2022, 7 (2), e00817-21. 10.1128/msphere.00817-21. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Buldain I.; Pellon A.; Zaldibar B.; Antoran A.; Martin-Souto L.; Aparicio-Fernandez L.; Areitio M.; Mayayo E.; Rementeria A.; Hernando F. L.; Ramirez-Garcia A. Study of Humoral Responses against Lomentospora/Scedosporium spp. And Aspergillus fumigatus to Identify L. prolificans Antigens of Interest for Diagnosis and Treatment. Vaccines 2019, 7 (4), 212. 10.3390/vaccines7040212. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Martoja R.; Martoja-Pierson M.. Técnicas de Histología Animal; Toray-Masson: Barcelona, 1970. [Google Scholar]
  22. Gomori G. A New Histochemical Test for Glycogen and Mucin. Am. J. Clin. Pathol. 1946, 16 (6), 177–179. 10.1093/ajcp/16.11_ts.177. [DOI] [PubMed] [Google Scholar]
  23. Pellon A.; Ramirez-Garcia A.; Buldain I.; Antoran A.; Rementeria A.; Hernando F. L. Immunoproteomics-Based Analysis of the Immunocompetent Serological Response to Lomentospora prolificans. J. Proteome Res. 2016, 15 (2), 595–607. 10.1021/acs.jproteome.5b00978. [DOI] [PubMed] [Google Scholar]
  24. Buldain I.; Ramirez-Garcia A.; et al. Cyclophilin and Enolase Are the Most Prevalent Conidial Antigens of Lomentospora prolificans Recognized by Healthy Human Salivary IgA and Cross-React with Aspergillus fumigatus. PROTEOMICS - Clin. Appl. 2016, 10, 1058–1067. 10.1002/prca.201600080. [DOI] [PubMed] [Google Scholar]
  25. Perez-Riverol Y.; Bai J.; Bandla C.; García-Seisdedos D.; Hewapathirana S.; Kamatchinathan S.; Kundu D. J.; Prakash A.; Frericks-Zipper A.; Eisenacher M.; Walzer M.; Wang S.; Brazma A.; Vizcaíno J. A. The PRIDE Database Resources in 2022: A Hub for Mass Spectrometry-Based Proteomics Evidences. Nucleic Acids Res. 2022, 50 (D1), D543–D552. 10.1093/nar/gkab1038. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Singh R.; Kaur M.; Chakrabarti A.; Shankarnarayan S. A.; Rudramurthy S. M. Biofilm Formation by Candida auris Isolated from Colonising Sites and Candidemia Cases. Mycoses 2019, 62 (8), 706–709. 10.1111/myc.12947. [DOI] [PubMed] [Google Scholar]
  27. Wang X.; Bing J.; Zheng Q.; Zhang F.; Liu J.; Yue H.; Tao L.; Du H.; Wang Y.; Wang H.; Huang G. The First Isolate of Candida auris in China: Clinical and Biological Aspects Article. Emerging Microbes Infect. 2018, 7 (1), 1–9. 10.1038/s41426-018-0095-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Torres S. R.; Pichowicz A.; Torres-Velez F.; Song R.; Singh N.; Lasek-Nesselquist E.; De Jesus M. Impact of Candida auris Infection in a Neutropenic Murine Model. Antimicrob. Agents Chemother. 2020, 64 (3), 10–1128. 10.1128/AAC.01625-19. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Wang Y.; Zou Y.; Chen X.; Li H.; Yin Z.; Zhang B.; Xu Y.; Zhang Y.; Zhang R.; Huang X.; Yang W.; Xu C.; Jiang T.; Tang Q.; Zhou Z.; Ji Y.; Liu Y.; Hu L.; Zhou J.; Zhou Y.; Zhao J.; Liu N.; Huang G.; Chang H.; Fang W.; Chen C.; Zhou D. Innate Immune Responses against the Fungal Pathogen Candida auris. Nat. Commun. 2022, 13 (1), 3553. 10.1038/s41467-022-31201-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Forgács L.; Borman A. M.; Prépost E.; Tóth Z.; Kardos G.; Kovács R.; Szekely A.; Nagy F.; Kovacs I.; Majoros L. Comparison of in Vivo Pathogenicity of Four Candida auris Clades in a Neutropenic Bloodstream Infection Murine Model. Emerging Microbes Infect. 2020, 9 (1), 1160–1169. 10.1080/22221751.2020.1771218. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Rosario-colon J.; Eberle K.; Adams A.; Courville E.; Xin H. Candida Cell-surface-specific Monoclonal Antibodies Protect Mice against Candida auris Invasive Infection. Int. J. Mol. Sci. 2021, 22 (11), 6162. 10.3390/ijms22116162. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Garcia-Bustos V.; Ruiz-Saurí A.; Ruiz-Gaitán A.; Sigona-Giangreco I. A.; Cabañero-Navalon M. D.; Sabalza-Baztán O.; Salavert-Lletí M.; Tormo M. Á.; Pemán J. Characterization of the Differential Pathogenicity of Candida auris in a Galleria mellonella Infection Model. Microbiol. Spectr. 2021, 9 (1), 10–1128. 10.1128/Spectrum.00013-21. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Fakhim H.; Vaezi A.; Dannaoui E.; Chowdhary A.; Nasiry D.; Faeli L.; Meis J. F.; Badali H. Comparative Virulence of Candida auris with Candida haemulonii, Candida glabrata and Candida albicans in a Murine Model. Mycoses 2018, 61 (6), 377–382. 10.1111/myc.12754. [DOI] [PubMed] [Google Scholar]
  34. Xin H.; Mohiuddin F.; Tran J.; Adams A.; Eberle K. Experimental Mouse Models of Disseminated Candida auris Infection. mSphere 2019, 4 (5), 10–1128. 10.1128/mSphere.00339-19. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Pitarch A.; Díez-Orejas R.; Molero G.; Pardo M.; Sánchez M.; Gil C.; Nombela C. Analysis of the Serologic Response to Systemic Candida albicans Infection in a Murine Model. Proteomics 2001, 1 (4), 550–559. 10.1002/1615-9861(200104)1:4<550::AID-PROT550>3.0.CO;2-W. [DOI] [PubMed] [Google Scholar]
  36. Pitarch A.; Sánchez M.; Nombela C.; Gil C. Sequential Fractionation and Two-Dimensional Gel Analysis Unravels the Complexity of the Dimorphic Fungus Candida albicans Cell Wall Proteome. Mol. Cell. Proteomics 2002, 1 (12), 967–982. 10.1074/mcp.M200062-MCP200. [DOI] [PubMed] [Google Scholar]
  37. Barbosa M. S.; Báo S. N.; Andreotti P. F.; De Faria F. P.; Felipe M. S. S.; Feitosa L. D. S.; Mendes-Giannini M. J. S.; Soares C. M. D. A. Glyceraldehyde-3-Phosphate Dehydrogenase of Paracoccidioides brasiliensis Is a Cell Surface Protein Involved in Fungal Adhesion to Extracellular Matrix Proteins and Interaction with Cells. Infect. Immun. 2006, 74 (1), 382–389. 10.1128/IAI.74.1.382-389.2006. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Gozalbo D.; Gil-Navarro I.; Azorín I.; Renau-Piqueras J.; Martínez J. P.; Gil M. L. The Cell Wall-Associated Glyceraldehyde-3-Phosphate Dehydrogenase of Candida albicans Is Also a Fibronectin and Laminin Binding Protein. Infect. Immun. 1998, 66 (5), 2052–2059. 10.1128/IAI.66.5.2052-2059.1998. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Satala D.; Zelazna A.; Satala G.; Bukowski M.; Zawrotniak M.; Rapala-Kozik M.; Kozik A. Towards Understanding the Novel Adhesin Function of Candida albicans Phosphoglycerate Mutase at the Pathogen Cell Surface: Some Structural Analysis of the Interactions with Human Host Extracellular Matrix Proteins. Acta Biochim. Polym. 2021, 68 (4), 515–525. 10.18388/abp.2020_5959. [DOI] [PubMed] [Google Scholar]
  40. Weerasinghe H.; Simm C.; Djajawi T. M.; Tedja I.; Lo T. L.; Simpson D. S.; Shasha D.; Mizrahi N.; Olivier F. A. B.; Speir M.; Lawlor K. E.; Ben-Ami R.; Traven A. Candida auris Uses Metabolic Strategies to Escape and Kill Macrophages While Avoiding Robust Activation of the NLRP3 Inflammasome Response. Cell Rep. 2023, 42 (5), 112522. 10.1016/j.celrep.2023.112522. [DOI] [PubMed] [Google Scholar]
  41. Singh B.; Sharma G. L.; Oellerich M.; Kumar R.; Singh S.; Bhadoria D. P.; Katyal A.; Reichard U.; Asif A. R. Novel Cytosolic Allergens of Aspergillus fumigatus Identified from Germinating Conidia. J. Proteome Res. 2010, 9 (11), 5530–5541. 10.1021/pr100605c. [DOI] [PubMed] [Google Scholar]
  42. Rodrigues A. M.; Kubitschek-Barreira P. H.; Pinheiro B. G.; Teixeira-Ferreira A.; Hahn R. C.; de Camargo Z. P. Immunoproteomic Analysis Reveals Novel Candidate Antigens for the Diagnosis of Paracoccidioidomycosis Due to Paracoccidioides lutzii. J. Fungi 2020, 6 (4), 357. 10.3390/jof6040357. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. He Z.; Piao J.; Qiu Y.; Lei D.; Yang Y.; Shi L.; Wang F. Investigation of the Location and Secretion Features of Candida albicans Enolase with Monoclonal Antibodies. Ann. Microbiol. 2022, 72 (1), 25. 10.1186/s13213-022-01682-8. [DOI] [Google Scholar]
  44. Silva R. C.; Padovan A. C. B.; Pimenta D. C.; Ferreira R. C.; da Silva C. V.; Briones M. R. S. Extracellular Enolase of Candida albicans Is Involved in Colonization of Mammalian Intestinal Epithelium. Front. Cell. Infect. Microbiol. 2014, 4, 66. 10.3389/fcimb.2014.00066. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Karkowska-Kuleta J.; Wronowska E.; Satala D.; Zawrotniak M.; Bras G.; Kozik A.; Nobbs A. H.; Rapala-Kozik M. Als3-Mediated Attachment of Enolase on the Surface of Candida albicans Cells Regulates Their Interactions with Host Proteins. Cell. Microbiol. 2021, 23 (4), e13297. 10.1111/cmi.13297. [DOI] [PubMed] [Google Scholar]
  46. He Z. X.; Chen J.; Li W.; Cheng Y.; Zhang H. P.; Zhang L. N.; Hou T. W. Serological Response and Diagnostic Value of Recombinant Candida Cell Wall Protein Enolase, Phosphoglycerate Kinase, and β-Glucosidase. Front. Microbiol. 2015, 6, 151384. 10.3389/fmicb.2015.00920. [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. He Z. X.; Shi L. C.; Ran X. Y.; Li W.; Wang X. L.; Wang F. K. Development of a Lateral Flow Immunoassay for the Rapid Diagnosis of Invasive Candidiasis. Front. Microbiol. 2016, 7, 212453. 10.3389/fmicb.2016.01451. [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. van Deventer H. J.; Goessens W. H.; Van Vliet A. J.; Verbrugh H. A. Anti-Enolase Antibodies Partially Protective against Systemic Candidiasis in Mice. Clin. Microbiol. Infect. 1996, 2 (1), 36–43. 10.1111/j.1469-0691.1996.tb00198.x. [DOI] [PubMed] [Google Scholar]
  49. Qing Li W.; Chu Hu X.; Zhang X.; Ge Y.; Zhao S.; Hu Y.; Ashman R. B. Immunisation with the Glycolytic Enzyme Enolase Confers Effective Protection against Candida albicans Infection in Mice. Vaccine 2011, 29 (33), 5526–5533. 10.1016/j.vaccine.2011.05.030. [DOI] [PubMed] [Google Scholar]
  50. Montagnoli C.; Sandini S.; Bacci A.; Romani L.; La Valle R. Immunogenicity and Protective Effect of Recombinant Enolase of Candida albicans in a Murine Model of Systemic Candidiasis. Med. Mycol. 2004, 42 (4), 319–324. 10.1080/13693780310001644653. [DOI] [PubMed] [Google Scholar]
  51. Calcedo R.; Ramirez-Garcia A.; Abad A.; Rementeria A.; Pontón J.; Hernando F. L. Phosphoglycerate Kinase and Fructose Bisphosphate Aldolase of Candida albicans as New Antigens Recognized by Human Salivary IgA. Rev. Iberoam. Micol. 2012, 29 (3), 172–174. 10.1016/j.riam.2011.07.004. [DOI] [PubMed] [Google Scholar]
  52. Medrano-Díaz C. L.; Vega-González A.; Ruiz-Baca E.; Moreno A.; Cuéllar-Cruz M. Moonlighting Proteins Induce Protection in a Mouse Model against Candida Species. Microb. Pathog. 2018, 124, 21–29. 10.1016/j.micpath.2018.08.024. [DOI] [PubMed] [Google Scholar]
  53. Gil-Navarro I.; Gil M. L.; Casanova M.; O’Connor J. E.; Martínez J. P.; Gozalbo D. The Glycolytic Enzyme Glyceraldehyde-3-Phosphate Dehydrogenase of Candida albicans Is a Surface Antigen. J. Bacteriol. 1997, 179 (16), 4992–4999. 10.1128/jb.179.16.4992-4999.1997. [DOI] [PMC free article] [PubMed] [Google Scholar]
  54. Gil M. L.; Villamón E.; Monteagudo C.; Gozalbo D.; Martínez J. P. Clinical Strains of Candida albicans Express the Surface Antigen Glyceraldehyde 3-Phosphate Dehydrogenase in vitro and in Infected Tissues. FEMS Immunol. Med. Microbiol. 1999, 23 (3), 229–234. 10.1111/j.1574-695X.1999.tb01243.x. [DOI] [PubMed] [Google Scholar]
  55. Singh D. K.; Tóth R.; Gácser A. Mechanisms of Pathogenic Candida Species to Evade the Host Complement Attack. Front. Cell. Infect. Microbiol. 2020, 10, 94. 10.3389/fcimb.2020.00094. [DOI] [PMC free article] [PubMed] [Google Scholar]
  56. Gil M. L.; Dagan S.; Eren R.; Gozalbo D. Evaluation of the Usefulness of Anti-Glyceraldehyde-3-Phosphate Dehydrogenase Antibodies as a Treatment for Invasive Candidiasis in a Murine Model. Antonie van Leeuwenhoek 2006, 89 (3–4), 345–350. 10.1007/s10482-005-9037-7. [DOI] [PubMed] [Google Scholar]
  57. Pardo M.; Ward M.; Pitarch A.; Sánchez M.; Nombela C.; Blackstock W.; Gil C. Cross-Species Identification of Novel Candida albicans Immunogenic Proteins by Combination of Two-Dimensional Polyacrylamide Gel Electrophoresis and Mass Spectrometry. Electrophoresis 2000, 21 (13), 2651–2659. 10.1002/1522-2683(20000701)21:13<2651::AID-ELPS2651>3.0.CO;2-3. [DOI] [PubMed] [Google Scholar]
  58. Wang H. L.; Wen L. M.; Pei Y. J.; Wang F.; Yin L. T.; Bai J. Z.; Guo R.; Wang C. F.; Yin G. R. Recombinant Toxoplasma gondii Phosphoglycerate Mutase 2 Confers Protective Immunity against Toxoplasmosis in BALB/c Mice. Parasite 2016, 23, 12. 10.1051/parasite/2016012. [DOI] [PMC free article] [PubMed] [Google Scholar]
  59. Poltermann S.; Kunert A.; Von Der Heide M.; Eck R.; Hartmann A.; Zipfel P. F. Gpm1p Is a Factor H-, FHL-1-, and Plasminogen-Binding Surface Protein of Candida albicans. J. Biol. Chem. 2007, 282 (52), 37537–37544. 10.1074/jbc.M707280200. [DOI] [PubMed] [Google Scholar]
  60. Oho T.; Setoguchi D.; Nagata E. Surface-Expressed Phosphoglycerate Mutase of Candida albicans Binds to Salivary DMBT1. Arch. Microbiol. 2023, 205 (7), 263. 10.1007/s00203-023-03605-w. [DOI] [PubMed] [Google Scholar]
  61. Luo S.; Hipler U. C.; Münzberg C.; Skerka C.; Zipfel P. F. Sequence Variations and Protein Expression Levels of the Two Immune Evasion Proteins Gpm1 and Pra1 Influence Virulence of Clinical Candida albicans Isolates. PLoS One 2015, 10 (2), e0113192. 10.1371/journal.pone.0113192. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

pr3c00752_si_001.pdf (1.1MB, pdf)

Data Availability Statement

The raw MS data associated with this manuscript was submitted to the ProteomeXChange database and is available under the identifier PXD049077.


Articles from Journal of Proteome Research are provided here courtesy of American Chemical Society

RESOURCES